H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Reviva Pharmaceuticals to $20 from $10 and keeps a Buy rating on the shares. The company reported positive top-line data from the pivotal trial of brilaroxazine – a novel serotonin dopamine signaling modulator – in patients with schizophrenia, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on RVPH:
- Reviva data robust across multiple endpoints, says Roth MKM
- Reviva Announces Positive Topline Results from Global Pivotal Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia
- Reviva Pharmaceuticals announces Phase 3 RECOVER trial met primary endpoint
- Largest borrow rate increases among liquid names
- Reviva Pharmaceuticals: Last patient evaluated in Phase 3 RECOVER trial